Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 83 articles:
HTML format
Text format



Single Articles


    May 2019
  1. FLAHERTY RL, Intabli H, Falcinelli M, Bucca G, et al
    Stress hormone-mediated acceleration of breast cancer metastasis is halted by inhibition of nitric oxide synthase.
    Cancer Lett. 2019 May 24. pii: S0304-3835(19)30322.
    PubMed     Text format     Abstract available


  2. SANTIAGO-GOMEZ A, Kedward T, Simoes BM, Dragoni I, et al
    PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
    Cancer Lett. 2019 May 20. pii: S0304-3835(19)30309.
    PubMed     Text format     Abstract available


  3. SUN Q, Wang Y, Desgrosellier JS
    Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells.
    Cancer Lett. 2019 May 9. pii: S0304-3835(19)30280.
    PubMed     Text format     Abstract available


  4. MO D, Jiang P, YiningYang, Mao X, et al
    A tRNA fragment, 5'-tiRNA(Val), suppresses the Wnt/beta-Catenin signaling pathway by targeting FZD3 in breast cancer.
    Cancer Lett. 2019 May 9. pii: S0304-3835(19)30283.
    PubMed     Text format     Abstract available


    April 2019
  5. DONG Q, Yang B, Han JG, Zhang MM, et al
    A novel hydrogen sulfide-releasing donor, HA-ADT, suppresses the growth of human breast cancer cells through inhibiting the PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways.
    Cancer Lett. 2019 Apr 28. pii: S0304-3835(19)30268.
    PubMed     Text format     Abstract available


  6. WANG H, Yao F, Luo S, Ma K, et al
    A mutual activation loop between the Ca(2+)-activated chloride channel TMEM16A and EGFR/STAT3 signaling promotes breast cancer tumorigenesis.
    Cancer Lett. 2019 Apr 28. pii: S0304-3835(19)30264.
    PubMed     Text format     Abstract available


  7. SON D, Kim Y, Lim S, Kang HG, et al
    miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer.
    Cancer Lett. 2019;454:224-233.
    PubMed     Text format     Abstract available


  8. YANG Y, Zhu G, Dong B, Piao J, et al
    The NQO1/PKLR axis promotes lymph node metastasis and breast cancer progression by modulating glycolytic reprogramming.
    Cancer Lett. 2019;453:170-183.
    PubMed     Text format     Abstract available


    March 2019
  9. DIAZ-RODRIGUEZ E, Perez-Pena J, Rios-Luci C, Arribas J, et al
    TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells.
    Cancer Lett. 2019 Mar 27. pii: S0304-3835(19)30198.
    PubMed     Text format     Abstract available


  10. GUO L, Cheng X, Chen H, Chen C, et al
    Induction of breast cancer stem cells by M1 macrophages through Lin-28B-let-7-HMGA2 axis.
    Cancer Lett. 2019 Mar 24. pii: S0304-3835(19)30188.
    PubMed     Text format     Abstract available


  11. LIM JP, Nair S, Shyamasundar S, Chua PJ, et al
    Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression.
    Cancer Lett. 2019 Mar 21. pii: S0304-3835(19)30170.
    PubMed     Text format     Abstract available


  12. TANG X, Tu G, Yang G, Wang X, et al
    Autocrine TGF-beta1/miR-200s/miR-221/DNMT3B regulatory loop maintains CAF status to fuel breast cancer cell proliferation.
    Cancer Lett. 2019 Mar 6. pii: S0304-3835(19)30130.
    PubMed     Text format     Abstract available


    February 2019
  13. SOLINAS C, Marcoux D, Garaud S, Vitoria JR, et al
    BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
    Cancer Lett. 2019 Feb 21. pii: S0304-3835(19)30105.
    PubMed     Text format     Abstract available


  14. BISHOP RT, Marino S, de Ridder D, Allen RJ, et al
    Pharmacological inhibition of the IKKepsilon/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
    Cancer Lett. 2019 Feb 18. pii: S0304-3835(19)30110.
    PubMed     Text format     Abstract available


  15. AHMED K, Koval A, Xu J, Bodmer A, et al
    Towards the first targeted therapy for triple-negative breast cancer: repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30090.
    PubMed     Text format     Abstract available


  16. MARQUEZ-GARBAN DC, Gorrin-Rivas M, Chen HW, Sterling C Jr, et al
    Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30081.
    PubMed     Text format     Abstract available


  17. MA F, Liu X, Zhou S, Li W, et al
    Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30080.
    PubMed     Text format     Abstract available


  18. HE Q, Xue S, Tan Y, Zhang L, et al
    Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer.
    Cancer Lett. 2019 Feb 8. pii: S0304-3835(19)30070.
    PubMed     Text format     Abstract available


    January 2019
  19. FU S, Chen X, Lo HW, Lin J, et al
    Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
    Cancer Lett. 2019 Jan 29. pii: S0304-3835(19)30046.
    PubMed     Text format     Abstract available


  20. CHO TM, Kim JY, Kim YJ, Sung D, et al
    C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Cancer Lett. 2019 Jan 28. pii: S0304-3835(19)30049.
    PubMed     Text format     Abstract available


  21. ZHANG K, Hong R, Kaping L, Xu F, et al
    CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
    Cancer Lett. 2019 Jan 21. pii: S0304-3835(19)30017.
    PubMed     Text format     Abstract available


  22. YOON HJ, Kim DH, Kim SJ, Jang JH, et al
    Src-mediated phosphorylation, ubiquitination and degradation of Caveolin-1 promotes breast cancer cell stemness.
    Cancer Lett. 2019 Jan 20. pii: S0304-3835(19)30033.
    PubMed     Text format     Abstract available


    December 2018
  23. TU M, Lu C, Lv N, Wei J, et al
    Corrigendum to 'Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2' [Cancer Lett. 2016 Dec 28; 383 (2):272-281].
    Cancer Lett. 2018 Dec 26. pii: S0304-3835(18)30717.
    PubMed     Text format    


  24. ZHANG X, Gao D, Fang K, Guo Z, et al
    Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer progression by regulating the EGFR/MEK/ERK signaling pathway.
    Cancer Lett. 2018 Dec 21. pii: S0304-3835(18)30723.
    PubMed     Text format     Abstract available


  25. YUAN G, Lian Z, Liu Q, Lin X, et al
    Phosphatidyl Inositol 3-Kinase (PI3K)-mTOR Inhibitor PKI-402 Inhibits Breast Cancer Induced Osteolysis.
    Cancer Lett. 2018 Dec 9. pii: S0304-3835(18)30704.
    PubMed     Text format     Abstract available


    November 2018
  26. ZOU H, Sevigny MB, Liu S, Madden DT, et al
    Novel flexible heteroarotinoid, SL-1-39, inhibits HER2-positive breast cancer cell proliferation by promoting lysosomal degradation of HER2.
    Cancer Lett. 2018 Nov 29. pii: S0304-3835(18)30688.
    PubMed     Text format     Abstract available


  27. THAKUR V, Zhang K, Savadelis A, Zmina P, et al
    The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA Damage Response that impacts chemo- and radiotherapy responses of breast cancer.
    Cancer Lett. 2018 Nov 28. pii: S0304-3835(18)30697.
    PubMed     Text format     Abstract available


  28. YU L, Wang L, Mao C, Duraki D, et al
    Estrogen-Independent Myc Overexpression Confers Endocrine Therapy Resistance on Breast Cancer Cells Expressing ERalphaY537S and ERalphaD538G Mutations.
    Cancer Lett. 2018 Nov 9. pii: S0304-3835(18)30662.
    PubMed     Text format     Abstract available


  29. WANG X, Qi Y, Kong X, Zhai J, et al
    Recent Advances in the Research of Immunotherapy for Triple-Negative Breast Cancer.
    Cancer Lett. 2018 Nov 9. pii: S0304-3835(18)30664.
    PubMed     Text format     Abstract available


    October 2018
  30. GUPTA P, Gupta N, Fofaria NM, Ranjan A, et al
    HER2-mediated GLI2 stabilization promotes anoikis resistance and metastasis of breast cancer cells.
    Cancer Lett. 2018;442:68-81.
    PubMed     Text format     Abstract available


  31. SUN HF, Yang XL, Zhao Y, Tian Q, et al
    Loss of TMEM126A promotes extracellular matrix remodeling, epithelial-to-mesenchymal transition, and breast cancer metastasis by regulating mitochondrial retrograde signaling.
    Cancer Lett. 2018;440-441:189-201.
    PubMed     Text format     Abstract available


  32. WEN S, Hou Y, Fu L, Xi L, et al
    Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin beta3-p38 MAPK signalling.
    Cancer Lett. 2018 Oct 26. pii: S0304-3835(18)30629.
    PubMed     Text format     Abstract available


  33. XIAO YS, Zeng, Liang YK, Wu Y, et al
    Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells.
    Cancer Lett. 2018 Oct 15. pii: S0304-3835(18)30608.
    PubMed     Text format     Abstract available


  34. DING J, Wang X, Zhang Y, Sang X, et al
    Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kalpha inhibition through the transcriptional regulation of ERalpha.
    Cancer Lett. 2018 Oct 10. pii: S0304-3835(18)30605.
    PubMed     Text format     Abstract available


    September 2018
  35. ZHANG C, Zhang M, Song S
    Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation.
    Cancer Lett. 2018 Sep 15. pii: S0304-3835(18)30576.
    PubMed     Text format     Abstract available


  36. LIN CC, Lo MC, Moody R, Jiang H, et al
    Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
    Cancer Lett. 2018 Sep 15. pii: S0304-3835(18)30577.
    PubMed     Text format     Abstract available


    August 2018
  37. BARONE I, Vircillo V, Giordano C, Gelsomino L, et al
    Activation of Farnesoid X Receptor Impairs The Tumor-Promoting Function of Breast Cancer-Associated Fibroblasts.
    Cancer Lett. 2018 Aug 31. pii: S0304-3835(18)30544.
    PubMed     Text format     Abstract available


  38. WU Q, Chen D, Luo Q, Yang Q, et al
    Extracellular matrix protein 1 recruits moesin to facilitate invadopodia formation and breast cancer metastasis.
    Cancer Lett. 2018 Aug 27. pii: S0304-3835(18)30540.
    PubMed     Text format     Abstract available


  39. ZHANG H, Zhang Y, Chen C, Zhu X, et al
    A double-negative feedback loop between DEAD-box protein DDX21 and Snail regulates epithelial-mesenchymal transition and metastasis in breast cancer.
    Cancer Lett. 2018 Aug 27. pii: S0304-3835(18)30539.
    PubMed     Text format     Abstract available


  40. LOPES R, Korkmaz G, Revilla SA, van Vliet R, et al
    CUEDC1 is a primary target of ERalpha essential for the growth of breast cancer cells.
    Cancer Lett. 2018;436:87-95.
    PubMed     Text format     Abstract available


    July 2018
  41. DYCZYNSKI M, Yu Y, Otrocka M, Parpal S, et al
    Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.
    Cancer Lett. 2018 Jul 25. pii: S0304-3835(18)30486.
    PubMed     Text format     Abstract available


  42. NIKAS I, Ryu HS, Theocharis S
    Viewing the Eph receptors with a focus on breast cancer heterogeneity.
    Cancer Lett. 2018;434:160-171.
    PubMed     Text format     Abstract available


  43. FAN TC, Yeo HL, Hsu HM, Yu JC, et al
    Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells.
    Cancer Lett. 2018 Jul 21. pii: S0304-3835(18)30484.
    PubMed     Text format     Abstract available


  44. CHEN X, Liu P, Wang Q, Li Y, et al
    DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
    Cancer Lett. 2018 Jul 11. pii: S0304-3835(18)30470.
    PubMed     Text format     Abstract available


  45. LIU XL, Xu YC, Wang YX, Chen Y, et al
    Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kalpha-selective inhibitor CYH33 in breast cancer.
    Cancer Lett. 2018 Jul 9. pii: S0304-3835(18)30469.
    PubMed     Text format     Abstract available


    June 2018
  46. GU J, Wang Y, Wang X, Zhou D, et al
    Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer.
    Cancer Lett. 2018 Jun 30. pii: S0304-3835(18)30447.
    PubMed     Text format     Abstract available


  47. XIAO Y, Li Y, Tao H, Humphries B, et al
    Integrin alpha5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
    Cancer Lett. 2018 Jun 29. pii: S0304-3835(18)30445.
    PubMed     Text format     Abstract available


  48. SALINAS-VERA YM, Marchat LA, Garcia-Vazquez R, Gonzalez de la Rosa CH, et al
    Cooperative multi-targeting of signaling networks by angiomiR-204 inhibits vasculogenic mimicry in breast cancer cells.
    Cancer Lett. 2018;432:17-27.
    PubMed     Text format     Abstract available


  49. SAUVAGE F, Fattal E, Al-Shaer W, Denis S, et al
    Antitumor activity of nanoliposomes encapsulating the novobiocin analogue 6BrCaQ in a triple-negative breast cancer model in mice.
    Cancer Lett. 2018 Jun 5. pii: S0304-3835(18)30397.
    PubMed     Text format     Abstract available


    May 2018
  50. WU J, Jiang Z, Chen C, Hu Q, et al
    CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis.
    Cancer Lett. 2018;430:179-192.
    PubMed     Text format     Abstract available


  51. SOHN EJ, Jung DB, Lee H, Han I, et al
    Corrigendum to "CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells" [Cancer Lett 412 (2018 Jan 1) 88-98].
    Cancer Lett. 2018 May 19. pii: S0304-3835(18)30321.
    PubMed     Text format    


  52. LI Y, Huang J, Zeng B, Yang D, et al
    PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation.
    Cancer Lett. 2018 May 16. pii: S0304-3835(18)30343.
    PubMed     Text format     Abstract available


  53. YAN M, Wang Y, Wong CW, Mei-Yu Or P, et al
    PTEN PDZ-binding domain suppresses mammary carcinogenesis in the MMTV-PyMT breast cancer model.
    Cancer Lett. 2018 May 14. pii: S0304-3835(18)30337.
    PubMed     Text format     Abstract available


  54. LIU Y, Geng YH, Yang H, Yang H, et al
    Extracellular ATP drives breast cancer cell migration and metastasis via S100A4 production by cancer cells and fibroblasts.
    Cancer Lett. 2018 May 4. pii: S0304-3835(18)30318.
    PubMed     Text format     Abstract available


    April 2018
  55. GELSOMINO L, Panza S, Giordano C, Barone I, et al
    Mutations in the Estrogen Receptor Alpha Hormone Binding Domain Promote Stem Cell Phenotype through Notch Activation in Breast Cancer Cell Lines.
    Cancer Lett. 2018 Apr 24. pii: S0304-3835(18)30290.
    PubMed     Text format     Abstract available


  56. OJO D, Lin X, Wu Y, Cockburn J, et al
    Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
    Cancer Lett. 2018;426:4-13.
    PubMed     Text format     Abstract available


    March 2018
  57. ZANOTTO-FILHO A, Rajamanickam S, Loranc E, Masamsetti P, et al
    Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells.
    Cancer Lett. 2018 Mar 30. pii: S0304-3835(18)30240.
    PubMed     Text format     Abstract available


  58. LAWSON JS, Salmons B, Gunzburg WH
    Commentary regarding Gannon et al. "Viral infections and breast cancer - A current perspective".
    Cancer Lett. 2018;424:117-118.
    PubMed     Text format    


  59. LI D, Wang H, Ding Y, Zhang Z, et al
    Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis.
    Cancer Lett. 2018;424:97-108.
    PubMed     Text format     Abstract available


  60. SUH J, Kim DH, Kim EH, Park SA, et al
    15-Deoxy-Delta(12,14)-prostaglandin J2 activates PI3K-Akt signaling in human breast cancer cells through covalent modification of the tumor suppressor PTEN at cysteine 136.
    Cancer Lett. 2018 Mar 14. pii: S0304-3835(18)30207.
    PubMed     Text format     Abstract available


  61. FERNANDEZ-NOGUEIRA P, Noguera-Castells A, Fuster G, Recalde-Percaz L, et al
    Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer.
    Cancer Lett. 2018 Mar 13. pii: S0304-3835(18)30205.
    PubMed     Text format     Abstract available


    February 2018
  62. HU Y, Yague E, Zhao J, Wang L, et al
    Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.
    Cancer Lett. 2018 Feb 26. pii: S0304-3835(18)30177.
    PubMed     Text format     Abstract available


  63. GANNON OM, Antonsson A, Bennett IC, Saunders NA, et al
    Viral infections and breast cancer - A current perspective.
    Cancer Lett. 2018 Feb 2. pii: S0304-3835(18)30117.
    PubMed     Text format     Abstract available


    January 2018
  64. LYU H, Wang S, Huang J, Wang B, et al
    Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Cancer Lett. 2018 Jan 30. pii: S0304-3835(18)30098.
    PubMed     Text format     Abstract available


  65. WANG QS, He R, Yang F, Kang LJ, et al
    FOXF2 deficiency permits basal-like breast cancer cells to form lymphangiogenic mimicry by enhancing the response of VEGF-C/VEGFR3 signaling pathway.
    Cancer Lett. 2018 Jan 30. pii: S0304-3835(18)30102.
    PubMed     Text format     Abstract available


  66. JIN Y, Hu W, Liu T, Rana U, et al
    Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.
    Cancer Lett. 2018 Jan 23. pii: S0304-3835(18)30087.
    PubMed     Text format     Abstract available


  67. GUO W, Hao B, Luo N, Ruan D, et al
    Early re-staging and molecular subtype shift surveillance of locally recurrent or metastatic breast cancer: A new PET/CT integrated precise algorithm.
    Cancer Lett. 2018 Jan 11. pii: S0304-3835(18)30041.
    PubMed     Text format     Abstract available


  68. ZIELINSKA HA, Holly JMP, Bahl A, Perks CM, et al
    Inhibition of FASN and ERalpha signalling during hyperglycaemia-induced matrix-specific EMT promotes breast cancer cell invasion via a caveolin-1-dependent mechanism.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30050.
    PubMed     Text format     Abstract available


  69. ZHOU KX, Xie LH, P X, Guo QM, et al
    CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation.
    Cancer Lett. 2018 Jan 6. pii: S0304-3835(18)30031.
    PubMed     Text format     Abstract available


    December 2017
  70. PLATONOV ME, Borovjagin AV, Kaverina N, Xiao T, et al
    KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy in vitro.
    Cancer Lett. 2017 Dec 18. pii: S0304-3835(17)30796.
    PubMed     Text format     Abstract available


  71. KIM HY, Ha Thi HT, Hong S
    IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor.
    Cancer Lett. 2017;415:30-39.
    PubMed     Text format     Abstract available


    November 2017
  72. CAI X, Wang X, Cao C, Gao Y, et al
    HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
    Cancer Lett. 2017 Nov 21. pii: S0304-3835(17)30740.
    PubMed     Text format     Abstract available


  73. KIM YJ, Sung D, Oh E, Cho Y, et al
    Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.
    Cancer Lett. 2017;412:118-130.
    PubMed     Text format     Abstract available


    October 2017
  74. LIANG S, Chen Z, Jiang G, Zhou Y, et al
    Corrigendum to "Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-kappaB/IL-6 signals" [Cancer Lett. 386 (2017) 12-23].
    Cancer Lett. 2017 Oct 30. pii: S0304-3835(17)30662.
    PubMed     Text format    


  75. BAI XY, Li S, Wang M, Li X, et al
    Kruppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion.
    Cancer Lett. 2017;412:224-235.
    PubMed     Text format     Abstract available


  76. SYNNOTT NC, Bauer MR, Madden S, Murray A, et al
    Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
    Cancer Lett. 2017 Oct 22. pii: S0304-3835(17)30622.
    PubMed     Text format     Abstract available


  77. WILMANSKI T, Zhou X, Zheng W, Shinde A, et al
    Inhibition of Pyruvate Carboxylase by 1alpha,25-Dihydroxyvitamin D Promotes Oxidative Stress in Early Breast Cancer Progression.
    Cancer Lett. 2017 Oct 9. pii: S0304-3835(17)30606.
    PubMed     Text format     Abstract available


  78. SOHN EJ, Jung DB, Lee H, Han I, et al
    CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells.
    Cancer Lett. 2017 Oct 9. pii: S0304-3835(17)30621.
    PubMed     Text format     Abstract available


  79. FIGUEIRA MI, Cardoso HJ, Correia S, Maia CJ, et al
    The stem cell factor (SCF)/c-KIT system in carcinogenesis of reproductive tissues: What does the hormonal regulation tell us?
    Cancer Lett. 2017;405:10-21.
    PubMed     Text format     Abstract available


    September 2017
  80. MARINO S, Bishop RT, Logan JG, Mollat P, et al
    Pharmacological evidence for the bone-autonomous contribution of the NFkappaB/beta-catenin axis to breast cancer related osteolysis.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30587.
    PubMed     Text format     Abstract available


  81. OLADAPO HO, Tarpley M, Sauer SJ, Addo KA, et al
    Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30586.
    PubMed     Text format     Abstract available


  82. XU H, Lin F, Wang Z, Yang L, et al
    CXCR2 Promotes Breast Cancer Metastasis and Chemoresistance via suppression of AKT1 and activation of COX2.
    Cancer Lett. 2017 Sep 27. pii: S0304-3835(17)30583.
    PubMed     Text format     Abstract available


  83. WANG S, Zhou R, Sun F, Li R, et al
    The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30551.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: